Exicure Inc. announced positive topline results from a completed Phase 2 clinical trial evaluating burixafor (GPC-100) in combination with propranolol and granulocyte colony-stimulating factor (G-CSF) for mobilizing hematopoietic progenitor cells (HPCs) in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation. The data, presented at the 2025 American Society of Hematology $(ASH)$ Annual Meeting, showed that approximately 90% of participants achieved the primary endpoint of collecting ≥2 × 10⁶ CD34+ cells/kg within two leukapheresis sessions. The study reported a favorable safety profile and rapid mobilization kinetics, with peak peripheral CD34+ cell levels observed within one hour of burixafor administration.